Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial

Affiliations

• ¹ Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
• ² Division of Haematology and Haemostasis, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
• ³ Department of Medicine, Hanusch Krankenhaus, Vienna, Austria.
• ⁴ University College London Hospitals (UCLH) Centre for Waldenströms Macroglobulinaemia and Related Conditions, UCLH, National Health Service (NHS) Foundation Trust, London, UK.
• ⁵ Worthing Hospital, Western Sussex Hospitals, NHS Foundation Trust, Worthing, UK.
• ⁶ Sanofi, Cambridge, Massachusetts, USA.
• ⁷ Sanofi, Warsaw, Poland.